on GENFIT (EPA:GNFT)
GENFIT: First Quarter 2025 Financial Results
GENFIT, a biopharmaceutical company, announced its financial results for the first quarter of 2025. Cash and cash equivalents as of March 31, 2025, stood at €129.5 million, compared to €74.0 million a year earlier. This increase was primarily due to a royalty financing agreement with HCRx, generating an initial payment of €130 million. However, €61.7 million was used to repurchase OCEANE shares.
Revenue for the period reached €2.8 million, largely driven by royalties on Ipsen's sales of Iqirvo® (elafibranor). In addition, the retirement of Chief Medical Officer Dr. Carol Addy was announced, with a replacement to be appointed.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news